ArticleNano-micro letters2020
Self-Assembly Protein Superstructures as a Powerful Chemodynamic Therapy Nanoagent for Glioblastoma Treatment.
Article in Nano-micro letters, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 42 citations in OpenAlex.
- A hemoglobin-based nanozyme with ruthenium-induced nanomotor ability exhibiting photothermal and chemodynamic responses.Mikrochimica acta · 2026Article
- Recent advances in self-assembled nanoplatforms for central nervous system disorders therapy: Design principles, multifunctional strategies, and therapeutic applications.Materials today. Bio · 2026Review
- CAR-neutrophils produced in vivo to treat glioma.Nature biomedical engineering · 2026Article
- Hemoglobin nanocatalyst with tunable autoxidation activity for tumor apoptosis-ferroptosis combination therapy.Acta pharmaceutica Sinica. B · 2025Article
- Two-pronged reversal of chemotherapy resistance by gold nanorods induced mild photothermal effect.Bioengineering & translational medicine · 2024Article
- Chemodynamic Therapy of Glioblastoma Multiforme and Perspectives.Pharmaceutics · 2024Review
- In Vivo High-Contrast Biomedical Imaging in the Second Near-Infrared Window Using Ultrabright Rare-Earth Nanoparticles.Nano letters · 2023Article
- Engineering Cell Membrane-Cloaked Catalysts as Multifaceted Artificial Peroxisomes for Biomedical Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Living Cells and Cell-Derived Vesicles: A Trojan Horse Technique for Brain Delivery.Pharmaceutics · 2023Review
- Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma.Pharmaceutics · 2023Review
- ROS regulation in gliomas: implications for treatment strategies.Frontiers in immunology · 2023Review
- Nanomaterials: small particles show huge possibilities for cancer immunotherapy.Journal of nanobiotechnology · 2022Review
- Rational Constructed Ultra-Small Iron Oxide Nanoprobes Manifesting High Performance forNanomaterials (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) remains a formidable challenge in oncology. Chemodynamic therapy (CDT) that triggers tumor cell death by reactive oxygen species (ROS) could open up a new door for GBM treatment. Herein, we report a novel CDT nanoagent. Hemoglobin (Hb) and glucose oxidase (GOx) were employed as powerful CDT catalysts. Instead of encapsulating the proteins in drug delivery nanocarriers, we formulate multimeric superstructures as self-delivery entities by crosslinking techniques. Red blood cell (RBC) membranes are camouflaged on the protein superstructures to promote the delivery across blood-brain barrier. The as-prepared RBC@Hb@GOx nanoparticles (NPs) offer superior biocompatibility, simplified structure, and high accumulation at the tumor site. We successfully demonstrated that the NPs could efficiently produce toxic ROS to kill U87MG cancer cells in vitro and inhibit the growth of GBM tumor in vivo, suggesting that the new CDT nanoagent holds great promise for treating GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.